{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"HealthTech Remedy","title":"Drug Repurposing: How Every Cure's AI Platform Unlocks Treatments for Diseases with founder Dr. David Fajgenbaum","html":"","width":"100%","height":180,"duration":2148,"description":"Could a cure for your disease already be sitting on a pharmacy shelf? In this episode, we explore the revolutionary work of Every Cure, a nonprofit on a mission to unlock the hidden potential of existing drugs through a groundbreaking approach to drug repurposing. We sit down with co-founder Dr. David Fajgenbaum, a physician-scientist who saved his own life by discovering a new use for an old drug after being diagnosed with the rare Castleman disease. His journey sparked a global movement to find treatments for the millions of patients suffering from diseases with no approved therapies. This episode dives deep into the systemic gaps in the pharmaceutical industry and how Every Cure is using cutting-edge technology to fill them. Dr. David Fajgenbaum shares his incredible personal story, from near-fatal illness to pioneering a new field of medical research. We discuss how his team is leveraging AI for drug discovery and rediscovery, building an AI platform that systematically matches thousands of approved drugs against thousands of diseases to find promising new treatments. This data-driven approach, which Dr. Fajgenbaum calls \"computational pharmacophenomics,\" is already yielding incredible results for both common and rare disease treatments. We explore the nonprofit's unique model, fueled by major funding from partners like ARPA-H and the TED Audacious Project, which allows them to pursue promising treatments that lack financial incentives for traditional development. You'll hear the stunning success stories of this drug repurposing strategy in action—from Leucovorin, a vitamin that is helping nonverbal children with autism speak their first words, to lidocaine, a common numbing agent showing a 29% reduction in mortality for breast cancer patients in a large clinical trial. This conversation reveals how technologies like biomedical knowledge graphs and large language models are accelerating the search for cures, turning a 100-day analysis into a 17-hour process...","thumbnail_url":"https://img.transistorcdn.com/Al9s4QJpRCg2VJ2YaV_fo3tDCayXbUO7NTDbnFeSAUQ/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mNTVk/OTAwMzQxYWFiZmYy/ZWFlNzFmN2RmOTcx/MDMwNy5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}